Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models

The fact that 10% of colorectal cancer tumors harbor BRAF V600E mutations suggested targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single-agent efficacy in this context. The potential for combination therapy has been shown by the BEACON trial where targeting the EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Khanh B., Kolekar, Sharada, Wang, Qian, Shih, Jen-Hsing, Buchanan, Christina M., Deva, Sanjeev, Shepherd, Peter R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716247/
https://www.ncbi.nlm.nih.gov/pubmed/36198029
http://dx.doi.org/10.1158/1535-7163.MCT-21-0941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716247/
https://www.ncbi.nlm.nih.gov/pubmed/36198029
http://dx.doi.org/10.1158/1535-7163.MCT-21-0941

Ejemplares similares